Expert Ratings for BioXcel Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 Wall Street analysts have provided ratings for BioXcel Therapeutics (NASDAQ:BTAI), with 7 bullish and 1 indifferent. The average 12-month price target is $10.12, representing an 83.13% decrease from the previous target of $60.00. Analysts predict stock performance based on company financials, meetings, and insider communications, typically updating their ratings quarterly or after major company events.
November 15, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioXcel Therapeutics received predominantly bullish ratings from analysts, but the average price target suggests a significant decrease from the previous target, indicating potential downward pressure on the stock price in the short term.
Despite the bullish sentiment from analysts, the drastic reduction in the average price target could lead to negative investor sentiment and a potential decrease in BTAI's stock price in the short term. The confidence level is not at the maximum due to the inherent unpredictability of market reactions and the fact that analyst ratings are not always accurate predictors of stock performance.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100